Business
Notification of US Patent Grant for VAL401
Notification of US Patent Grant for VAL401.
About this update from Valirx Plc
[{"type":"text","content":"\n \nRNS Number : 7339W ValiRx PLC 29 April 2016 \n\n \n \n29 April 2016\n \nValiRx Plc\n(\"ValiRx\" or \"the Company\")\n \nValiSeek Update\n \n\"Notification of US Patent Grant for VAL401\"\n \nValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, is pleased to announce that ValiSeek Limited (\"ValiSeek\"), the joint venture between ValiRx and Tangent Reprofiling Limited (\"Tangent\"), has received notification today from Tangent that a US patent covering the use of VAL401 as a treatment for adenocarcinoma has been allowed by the US patent office.\n \nAdding to the earlier US patent grant covering the composition of formulation for VAL401, as announced on 14 May 2015, the directors of ValiSeek believe this announcement to be further validation of the innovative scientific foundation behind and supporting the VAL401 project just as the up coming clinical trial has been designed to provide validation of the clinical applicability. \n \nDr Suzanne Dilly, CEO of ValiSeek Limited, commented: \"This further US patent has been allowed at an opportune moment as we progress through our clinical trial preparations. At such a late stage in our preparations of the Clinical Trial for VAL401 the fact that the compound is now in receipt of additional IP protection, adds value to shareholder funds and further endorses our joint venture.\"\n \nDr Satu Vainikka, CEO of ValiRx plc, added: \"This is a powerful confirmation of the science lieing behind VAL401 and I very much look forward to following VAL401 on its clinical trial pathway.\"\n \n- ENDS -\n \nFor further information on the Company, visit: www.valirx.com:\n \n\n\n\n\nValiRx plc\n\n\nTel: +44 (0) 20 3008 4416\n\n\n\n\nDr Satu Vainikka, Chief Executive\n\n\nTel: +44 (0) 20 3008 4416\n\n\n\n\nTarquin Edwards, Head of Communications.\n\n\nTel: +44 (0) 7879 458 364\[email protected]\n\n\n\n\nMark Treharne, Corporate Development Manager\n\n\nTel: +44 (0) 7736 564 686\[email protected]\n\n\n\n\n\n\n\n\n\n\n\n\nCairn Financial Advisers LLP (Nominated Adviser)\n\n\nTel: +44 (0) 20 7148 7900\n\n\n\n\nLiam Murray\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNorthland Capital Partners Limited (Broker)\n\n\nTel: +44 (0) 20 7382 1100\n\n\n\n\n...